A shadow economy for unapproved weight-loss medications is being driven by TikTok fitness influencers and sellers on messaging platforms, according to new investigations.
Experimental Drug Acquiring Traction Online
The experimental drug, which is still in clinical trials, is being promoted by social media influencers for its supposed weight-reducing effects. Followers are urged to message these accounts privately for supplier links, while also receiving promotional offers.
Active Trade on Messaging Platforms
Additionally, a flourishing trade exists on Telegram, where groups with thousands of participants share comparison images, administration instructions and claims of rapid UK delivery. Vendors promote the drug there before directing customers to other platforms for purchases.
Understanding The Experimental Drug
Retatrutide is an investigational injection created by US drugmaker Eli Lilly. The treatment targets three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist individuals reduce up to a quarter of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the successor to Ozempic.
Healthcare Experts Voice Worries
However, doctors and chemists have cautions that the sale of what is still an unlicensed drug in the United Kingdom is a cause for concern and could result in individuals administering substances of uncertain source.
Several professionals stated the popularity for retatrutide could be connected to the increasing price of approved slimming products such as Mounjaro.
Regulatory Status and Implementation
Selling retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that cannot be promoted or supplied for personal consumption under the British medical regulations.
Several influencers attempt to sidestep the regulations by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a restricted drug, but advertising and distribution can still breach pharmaceutical, marketing, and consumer regulations, potentially leading to penalties, prosecution or prison.
Service Response and Content Removal
Based on the social media company, the service has removed violative content and prohibited related keywords and query recommendations. The company said it was committed to keeping the service safe and investing in strengthening compliance measures.
Digital Marketplace Activities
Investigations also discovered communities with up to 9,000 participants marketing the experimental drug using Telegram's integrated discovery tool, which operates like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, filled with photos of slimming results, positive reviews and step-by-step instructions for mixing or injecting at residence.
Within minutes of joining one community, a seller shared contact information, where the majority of purchases occur. The vendor provided an instruction manual and guaranteed delivery within 48 hours. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. Not one inquired about body mass, medical conditions or previous experience.
Item Details and Pricing
Within these groups, messages show black plastic packages with Royal Mail stickers, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”
Buyers can choose between powder vials, mixed at residence with purified liquid, or pre-filled pens usually priced at £160 for 20mg. When asked how much time a pen should be used, vendors give conflicting responses ranging from a few weeks to “depends on your body”.
Service Oversight and Safety Actions
A representative for Telegram stated it actively moderated dangerous material on its service including material that encouraged the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Cautions
“Individuals are administering substances they cannot confirm. Although the science behind this drug is sound, these online versions may not contain what they advertise,” stated a pharmacy expert, the director of pharmacy at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current cost increases for approved slimming drugs such as Mounjaro. “With prices rising, patients are using social media. But counterfeit treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she said.
Her team has already seen individuals harmed by self-injection from unverified sources. “We recognize the frustration, but purchasing from messaging apps or communication platforms is taking chances with your health,” stated Wyllie. “These materials could be contaminated or incorrectly dosed.”
Producer Position
A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any government authority anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, noting that any item “misleadingly claiming itself as a Lilly investigational product not yet authorized … may expose users to possibly serious medical dangers”.
